# Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

> **NCT07723469** · PHASE3 · NOT_YET_RECRUITING · sponsor: **SURGE Therapeutics** · enrollment: 400 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** BCS + SRG-514
- **PROCEDURE:** BCS

## Key facts

- **NCT ID:** NCT07723469
- **Lead sponsor:** SURGE Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2034-10
- **Final completion:** 2034-10
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723469, "Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07723469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*